| Marker category |
Gene symbols |
| Non-HLA genes with risk SNPs [2] |
BACH 2 |
GALC |
MPHOSPH9 |
SP1 40 |
| BATF |
HHEX |
MPV17L2 |
STAT3 |
| CBLB |
IL12B |
MYB |
TAGAP |
| CD6 |
IL22RA2 |
MYC |
THEMIS |
| CLECL1 |
IL2RA |
NFKB 1 |
TMEM 39A |
| CLECL16A |
IRF8 |
NRM |
TNFRSF6B |
| CXCR5 |
KIF2IB |
OLIG3 |
TNFSF14 |
| CYP24A1 |
KPNB1/TBKBP1/TBX21 |
PLEK |
TNP2 |
| CYP27B1 |
MALT1 |
PTGER 4 |
TYK2 |
| DKKL1 |
MAPK1 |
PVT1 |
VCAM 1 |
| EOMES |
MERTK |
RGS 1 |
X |
| EPS15L1 |
MLANA |
RPS6KB1 |
ZFP36L1 |
| EVI 5 |
MMEL 1 |
SCO2 |
ZNF767 |
| HLA risk alleles [1-3] |
HLA C*05 |
HLA DRB*14 |
HLA DRB1*07 |
HLA DRB1*15:01 |
| HLA DRA*02 |
HLA DRB1*01:08 |
HLA DRB1*13:01 |
HLA DRB5 |
| HLA DRB*12 |
HLA DRB1*04:05 |
HLA DRB1*13:03 |
HLA G |
| Genes with with protective SNPs or Alleles [1,2,7,8] |
HLA B*44+HLA DRB1*1501 absent |
| HLA A*02 |
|
|
|
| NOTCH4 |
|
|
|
| Diagnostic marker on gene, RNA and/or cell level in PBMCs [1,2,4-8,36] |
ANXA (+) |
NPEPPS (+) |
CD58 (+) |
CDK4 (-) |
| C7orf54 (+) |
TRIB2 (+) |
CD40 (+) |
GNG2 (-) |
| CXCR4 (+) |
IL7R (+) |
ZMIZ1 (-) |
PAK2 (-) |
| ITPR1 (+) |
TNFAIP3 (+) |
TNFRSF1A (-) |
TGFBR2 (-) |
Genetic marker associated with treatment response
[1,2,5-8,36,68,88] |
CTSS (IFN b) |
LMP7 (IFN b) |
MxA (IFN b) |
HLA DRB1*04:08 (IFN b) |
| IFNAR1 (IFN b) |
IL7 (IFN b) |
MBP (GA) |
HLA DRB1*04:01 (IFN b) |
| FAS (GA) |
IL12RB2 (GA) |
IL1R1 (GA) |
|
(+)=upregulated mRNA levels and (-)=downregulated mRNA levels in PBMC from
MS patients; Genes with SNPs associated with treatment response to GA are
marked (GA) and to IFN beta are marked (IFN b) |
